Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
NuCana plc is a biotechnology business based in the US. NuCana shares (NCNA) are listed on the NASDAQ and all prices are listed in US Dollars. NuCana employs 27 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $2.77 |
|---|---|
| 52-week range | $1.88 - $7.07 |
| 50-day moving average | $2.56 |
| 200-day moving average | $2.77 |
| Wall St. target price | $1,168.72 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.03 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.77 from 2022-01-20
| 1 week (2022-01-13) | 2.21% |
|---|---|
| 1 month (2021-12-21) | 15.90% |
| 3 months (2021-10-21) | 7.78% |
| 6 months (2021-07-22) | 13.99% |
| 1 year (2021-01-22) | -55.03% |
|---|---|
| 2 years (2020-01-22) | -46.20% |
| 3 years (2019-01-22) | 14.63 |
| 5 years (2017-01-18) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -25.36% |
| Return on equity TTM | -41.71% |
| Profit margin | 0% |
| Book value | $1.50 |
| Market capitalisation | $149.2 million |
TTM: trailing 12 months
We're not expecting NuCana to pay a dividend over the next 12 months.
Over the last 12 months, NuCana's shares have ranged in value from as little as $1.88 up to $7.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NuCana's is 0.6555. This would suggest that NuCana's shares are less volatile than average (for this exchange).
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.